Design Therapeutics
DSGN

Design Therapeutics (DSGN) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$0.34
EPS estimate
−$0.33
EPS surprise
−3.03%
Revenue
$0.00
Reported
Aug 7, 2025

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 7, 2025−$0.33−$0.34−3.03%$0.00SEC
Q1 2025May 7, 2025−$0.28−$0.31−10.71%$0.00SEC
Q4 2024Mar 10, 2025−$0.27−$0.24+10.01%$0.00SEC
Q3 2024Nov 7, 2024−$0.24−$0.23+5.47%$0.00SEC
Q2 2024Aug 5, 2024−$0.23−$0.21+9.99%$0.00SEC
Q1 2024May 8, 2024−$0.26−$0.20+24.04%$0.00SEC
Q4 2023Mar 19, 2024−$0.31−$0.21+32.26%$0.00SEC
Q3 2023Nov 13, 2023−$0.41−$0.28+31.29%$0.00SEC
Q2 2023Aug 14, 2023−$0.40−$0.36+9.43%$0.00SEC
Q1 2023May 9, 2023−$0.36−$0.35+2.23%$0.00SEC
Q4 2022Mar 14, 2023−$0.34−$0.31+9.88%$0.00SEC
Q3 2022Nov 3, 2022−$0.29−$0.32−11.11%$0.00SEC
Q2 2022Aug 8, 2022−$0.25−$0.27−8.00%$0.00SEC
Q1 2022May 9, 2022−$0.22−$0.24−9.09%$0.00SEC
Q4 2021Mar 10, 2022−$0.23−$0.20+11.78%$0.00SEC
Q3 2021Nov 9, 2021−$0.14−$0.21−50.00%$0.00SEC
Q2 2021Aug 9, 2021−$0.18−$0.14+22.22%$0.00SEC
Q1 2021May 10, 2021−$0.24−$0.31−30.97%$0.00SEC

Quarterly revenue

Q1 2021
$0.00
Q2 2021
$0.00
Q3 2021
$0.00
Q4 2021
$0.00
Q1 2022
$0.00
Q2 2022
$0.00
Q3 2022
$0.00
Q4 2022
$0.00
Q1 2023
$0.00
Q2 2023
$0.00
Q3 2023
$0.00
Q4 2023
$0.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00

Frequently asked questions

  • When did Design Therapeutics (DSGN) last report earnings?

    Design Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.

  • Did DSGN beat earnings estimates?

    No. Design Therapeutics reported EPS of −$0.34 for Q2 2025 against a −$0.33 estimate — a 3.03% miss.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.